Back
About the Global Fund
People & Structures
Back
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
HIV & AIDS
Tuberculosis
Malaria
Back
News
-
12 January 2021
Global Fund signs a record-breaking $8.54 billion in grants -
22 December 2020
Global Fund has awarded $1 billion to support countries’ COVID-19 responses, but funding for this purpose is now fully deployed -
21 December 2020
Denmark, Norway and Sweden Support Global Fund’s COVID-19 Response By Contributing a Total US$45 million -
14 December 2020
Canada Contributes CAD 65 million to Global Fund’s COVID-19 Response
Updates
-
15 January 2021
2020 Applicant Survey Shows High-Level of Satisfaction with Global Fund’s Application Process -
13 January 2021
COVID-19 Situation Report -
12 January 2021
Global Fund signs a record-breaking $8.54 billion in grants to fight HIV, TB and malaria -
07 January 2021
Strategic Review 2020 of the Global Fund now available
Stories
-
18 December 2020
A Look Back at 2020 -
17 December 2020
Data saves lives. To end HIV, we must improve key population data collection now. -
10 December 2020
Put Human Rights at the Centre of our Battle Against COVID-19 -
10 December 2020
Kiki’s story: Defending transgender rights during COVID-19 in Cameroon -
02 December 2020
How the lessons the world learned in the fight against HIV can help us defeat COVID-19 -
01 December 2020
Without Equity, We Cannot End COVID-19, HIV Or Any Other Pandemic
Back
Featured Publication
Documents by type
Opportunity for Evaluation of Selected Medicines
20 November 2020
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
Detailed information about the review process and submission requirements for this Round 23 opportunity can be found in the document below.
Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.
The deadline for submission of an expression of interest is Friday 08 January 2021 (COB). At the end of January 2021, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of documents submitted. The results of the product evaluations are expected for release by the end of March 2021.
- Invitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical ProductsInvitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.